Effects of carvedilol on murine viral myocarditis
- VernacularTitle:卡维地洛对病毒性心肌炎小鼠的保护作用及其机制
- Author:
Dan WANG
;
Jianbin JIANG
;
Maoping CHU
;
Yan QIAN
;
Qi CHEN
- Publication Type:Journal Article
- Keywords:
Myocarditis;
Carvedilol;
p38 mitogen-activated protein kinase
- From:
Chinese Journal of Pathophysiology
2009;25(12):2319-2322
- CountryChina
- Language:Chinese
-
Abstract:
AIM: To observe the effects of carvedilol on murine viral myocarditis model. METHODS: A total of 188 inbred male BALB/c mice of 4-6 weeks were divided into 4 groups: myocarditis group (group C, n=60), metoprolol treatment group (group M, n=60), carvedilol treatment group (group K, n=60), control group (group B, n=8). Myocardial histopathololgic changes were observed. The concentrations of cardiac troponin I (cTn-I) were detected by chemiluminescence immunoassay (CLIA). Western blotting was performed to analyze the contents of phosphorylated p38MAPK in myocardium. RESULTS: Metropolol and carvedilol lightened myocardial histopathololgic changes at acute stage, decreased cTn-I concentrations and myocardial phosphorylated p38MAPK value compared with myocarditis group. Treatment with carvedilol was more effective than treated with metropolol on those indexes. CONCLUSION: Carvedilol protects against viral myocarditis by inhibition of p38MAPK signal transduction pathway through blockade of β_1 and β_2 adrenergic receptors.
